| 89.05 2.04 (2.34%) | 10-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 124.6  |
1-year : | 140.89 |
| Resists | First : | 106.67 |
Second : | 120.62 |
| Pivot price | 95.01 |
|||
| Supports | First : | 84.11 |
Second : | 69.97 |
| MAs | MA(5) : | 89.77 |
MA(20) : | 98.66 |
| MA(100) : | 114.75 |
MA(250) : | 115.5 |
|
| MACD | MACD : | -6.7 |
Signal : | -6.2 |
| %K %D | K(14,3) : | 9.3 |
D(3) : | 7 |
| RSI | RSI(14): 33 |
|||
| 52-week | High : | 148.83 | Low : | 69.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ABVX ] has closed above bottom band by 20.8%. Bollinger Bands are 36.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 89.42 - 90.01 | 90.01 - 90.55 |
| Low: | 82.69 - 83.42 | 83.42 - 84.08 |
| Close: | 87.87 - 89.07 | 89.07 - 90.16 |
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
Fri, 09 Oct 2026
Abivax SA Stock 12‑Month Price Target Cut to $159.06, Implies 79% Upside - TradingView
Thu, 08 Oct 2026
Western Standard LLC's Abivax SA(ABVX) Holding History - GuruFocus
Wed, 07 Oct 2026
ABIVAX Société Anonyme (ABVX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tue, 06 Oct 2026
676,589 Shares in Abivax SA Sponsored ADR $ABVX Acquired by Two Seas Capital LP - MarketBeat
Tue, 06 Oct 2026
Abivax Slips as Investors Weigh Regulatory Timing After Recent Updates - Moomoo
Mon, 05 Oct 2026
(ABVX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 87 (M) |
| Held by Insiders | 6.903e+007 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 6,000 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.9155e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 617.9 % |
| Return on Equity (ttm) | -62.9 % |
| Qtrly Rev. Growth | 4.67e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -6.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -197 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.27 |
| Dividend | 0 |
| Forward Dividend | 6.86e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|